Home/ Stocks/ FULC

Fulcrum Therapeutics, Inc. Common Stock

FULC XNAS

$3.89 +0.12 (+3.18%) ▲ 15-min delayed

Open

$3.83

High

$3.91

Low

$3.77

Volume

1.46M

Market Cap

$287.64M

About Fulcrum Therapeutics, Inc. Common Stock

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 55 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q2 2026	$0	$-26,179,000	$-0.34
Q1 2026	$0	$-18,891,000	$-0.25
Q2 2025	$0	$-17,296,000	$-0.28
Q1 2025	$0	$-17,655,000	$-0.28

Related Market News

No specific coverage for FULC yet. Check out our latest market news or earnings calendar.

Get FULC Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Fulcrum Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.